Viatris agreed to acquire PPacira BioSciences, adding EXPAREL and ZILRETTA to its portfolio of non-opioid pain medicines. The transaction creates a larger commercial platform for Pacira’s marketed products, but its value depends on closing and on Viatris expanding their reach.
Viatris said it agreed to acquire Pacira BioSciences, whose marketed medicines include EXPAREL and ZILRETTA. The products are patent-protected and described as high-margin medicines in the U.S.; Viatris plans to use its international infrastructure and expand its U.S. innovative-medicines commercial, market-access and medical-affairs operations around them.
Pacira reported 2025 revenue of $726.4 million, up 3.6% year over year, with diluted EPS of $0.16 and a 1.0% net margin. The transaction would move those products into Viatris’ broader commercial organization, while the deal’s completion and terms remain central to the outcome.
Our take
1 / 6
Our read · Oct 8
Viatris agreed to acquire Pacira for its EXPAREL and ZILRETTA non-opioid pain medicines.
Why
The transaction gives Pacira’s two marketed medicines access to Viatris’ commercial and international infrastructure, but the near-term read depends on execution and the economics of the acquisition. Pacira’s 2025 revenue was $726.4 million with a 1.0% net margin, so the strategic rationale is clearer than the immediate earnings effect; the next quarterly results should show whether product demand and integration are translating into operating performance.
What could change this view
The read fails if the acquisition does not close or if Viatris cannot expand EXPAREL and ZILRETTA sales without eroding their economics.
▲ The case it holds
Viatris can use its established infrastructure to broaden two patent-protected products beyond Pacira’s existing commercial reach, building on Pacira’s $726.4 million of 2025 revenue.
▼ The case it breaks
Pacira’s 2025 revenue grew only 3.6% and its net margin was 1.0%, leaving limited evidence that the products will quickly deliver the high-margin growth Viatris expects.
Reported by PR Newswire as Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies, . Who answers for this
Prices: 1D EOD · OCT 7 CLOSE, licensed end-of-day data.
Source: PR Newswire · Published here THU, OCT 8 · 7:45 AM ET · the only report in this record · How this is decided →
Photo: PR Newswire / file
Kept as written · your side, if you take one, is graded privately against licensed closes after 10 trading days · reaction = the first close after a story against the close before it · nothing here is advice · How the Wire is made →
Related stocks
Not in this story
Same industry as PCRX (Pharmaceutical Preparations). Shown for context; the story doesn't mention them.
Photo credit ↓